Ascendis considers selling entire biosciences division
Ascendis has also been in talks about a possible sale of its Remedica business in Cyprus, which is seen as key to reducing Ascendis’s debt
Ascendis Health, whose shares have slumped on concerns about its debt levels and weak organic growth, says it is considering selling the two remaining businesses in its biosciences division after it offloaded three companies in that unit.
The sale of Afrikelp, Efekto and Marltons, announced in May, is now complete after receiving approval from competition authorities, Ascendis said on Wednesday. The businesses were sold to a consortium comprising RMB Ventures Seven, Nedbank Private Equity and some managers at Ascendis’s biosciences division. ..